Video
6 Oct 2020
BioVectra's CDMO Capabilities
.JPG)
BioVectra offers contract development and manufacturing capacity for intermediates and active pharmaceutical ingredients (APIs) from five North American cGMP facilities. We specialize in Microbial Fermentation, Complex Chemistry, Biologics, and Formulation Development.
Content provided by our supplier
Agilent Advanced Therapeutics (Formerly BIOVECTRA)
-
Country/Region:Canada
-
On CPHI since:2015
-
Certificates:2
-
Employees:500 - 999
Company types
Primary activities
Other Content from Agilent Advanced Therapeutics (Formerly BIOVECTRA) (4)
-
Brochure BIOVECTRA Company Overview
Learn more about BIOVECTRA in this company overview. -
.JPG)
Whitepaper Enabling Commercial Manufacturing for Highly Complex Small Molecule Drugs through Process Engineering and Technological Innovation
This case study presents the successful collaboration between an early-stage company that was struggling with the development of a realistic and economically viable commercial pathway and BioVectra, a CDMO with 50 years of experience. -
.jpg)
Whitepaper An Innovative Approach to Manufacturing Biologics using Microbial Fermentation
This Whitepaper outlines what a platform technology is and how it can speed up process development, the impact of high-throughput technologies, and what single-use, disposable technologies are currently on the market for biologics manufacturing. -
.JPG)
Whitepaper Supporting Client Projects for CDMO Success
The production of increasingly complex small molecule APIs is challenging. CDMOs with multiple capabilities are needed to develop efficient routes to synthesize these complicated molecules. This paper outlines how BioVectra supports client projects.